Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 21, Issue 1, pp. 134-147
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 11, 2011
- Revision received October 18, 2011
- Accepted November 14, 2011
- Published first December 5, 2011.
Article Versions
- Previous version (December 5, 2011 - 07:22).
- Previous version (December 15, 2011 - 07:22).
- You are viewing the most recent version of this article.
Copyright & Usage
©2011 American Association for Cancer Research.
Author Information
- Nasim Mavaddat1,
- Daniel Barrowdale1,
- Irene L. Andrulis2,5,
- Susan M. Domchek9,
- Diana Eccles11,
- Heli Nevanlinna12,
- Susan J. Ramus15,
- Amanda Spurdle17,
- Mark Robson3,
- Mark Sherman18,
- Anna Marie Mulligan6,7,
- Fergus J. Couch20,
- Christoph Engel24,
- Lesley McGuffog1,
- Sue Healey17,
- Olga M. Sinilnikova25,26,
- Melissa C. Southey28,
- Mary Beth Terry4,
- David Goldgar30,
- Frances O'Malley2,5,
- Esther M. John31,
- Ramunas Janavicius32,
- Laima Tihomirova33,
- Thomas V. O. Hansen34,
- Finn C. Nielsen34,
- Ana Osorio36,
- Alexandra Stavropoulou38,
- Javier Benítez36,
- Siranoush Manoukian39,
- Bernard Peissel39,
- Monica Barile41,
- Sara Volorio42,
- Barbara Pasini43,
- Riccardo Dolcetti44,
- Anna Laura Putignano45,
- Laura Ottini46,
- Paolo Radice40,42,
- Ute Hamann47,
- Muhammad U. Rashid47,49,
- Frans B. Hogervorst50,
- Mieke Kriege52,
- Rob B. van der Luijt53; for HEBON51,
- Susan Peock1,
- Debra Frost1,
- D. Gareth Evans54,
- Carole Brewer55,
- Lisa Walker56,
- Mark T. Rogers57,
- Lucy E. Side58,
- Catherine Houghton59; for EMBRACE1,
- JoEllen Weaver10,
- Andrew K. Godwin60,
- Rita K. Schmutzler61,
- Barbara Wappenschmidt61,
- Alfons Meindl62,
- Karin Kast63,
- Norbert Arnold64,
- Dieter Niederacher65,
- Christian Sutter48,
- Helmut Deissler66,
- Doroteha Gadzicki67,
- Sabine Preisler-Adams68,
- Raymonda Varon-Mateeva69,
- Ines Schönbuchner70,
- Heidrun Gevensleben71,
- Dominique Stoppa-Lyonnet72,73,74,
- Muriel Belotti72,
- Laure Barjhoux26; for GEMO Study Collaborators27,
- Claudine Isaacs75,
- Beth N. Peshkin75,
- Trinidad Caldes37,
- Miguel de la Hoya37,
- Carmen Cañadas37,
- Tuomas Heikkinen12,
- Päivi Heikkilä13,
- Kristiina Aittomäki14,
- Ignacio Blanco77,
- Conxi Lazaro77,
- Joan Brunet78,
- Bjarni A. Agnarsson79,
- Adalgeir Arason79,
- Rosa B. Barkardottir79,
- Martine Dumont80,
- Jacques Simard81,
- Marco Montagna82,
- Simona Agata82,
- Emma D'Andrea83,
- Max Yan84,
- Stephen Fox29; for kConFab Investigators29,
- Timothy R. Rebbeck8,
- Wendy Rubinstein85,
- Nadine Tung86,
- Judy E. Garber87,
- Xianshu Wang21,
- Zachary Fredericksen20,
- Vernon S. Pankratz20,
- Noralane M. Lindor23,
- Csilla Szabo88,
- Kenneth Offit3,
- Rita Sakr3,
- Mia M. Gaudet89,
- Christian F. Singer90,
- Muy-Kheng Tea90,
- Christine Rappaport90,
- Phuong L. Mai19,
- Mark H. Greene19,
- Anna Sokolenko91,
- Evgeny Imyanitov91,
- Amanda Ewart Toland92,
- Leigha Senter93,
- Kevin Sweet93,
- Mads Thomassen94,
- Anne-Marie Gerdes35,
- Torben Kruse94,
- Maria Caligo95,
- Paolo Aretini95,
- Johanna Rantala96,
- Anna von Wachenfeld97,
- Karin Henriksson99; for SWE-BRCA Collaborators98,
- Linda Steele100,
- Susan L. Neuhausen100,
- Robert Nussbaum101,
- Mary Beattie102,
- Kunle Odunsi103,
- Lara Sucheston104,
- Simon A. Gayther15,
- Kate Nathanson9,
- Jenny Gross16,
- Christine Walsh16,
- Beth Karlan16,
- Georgia Chenevix-Trench17,
- Douglas F. Easton1, and
- Antonis C. Antoniou1; for the Consortium of Investigators of Modifiers of BRCA1/2
- Authors' Affiliations: 1Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 2Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital; 3Departments of Medicine, Surgery, and Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center; 4Department of Epidemiology, Columbia University, New York; Departments of 5Molecular Genetics and 6Laboratory Medicine and Pathobiology, University of Toronto; 7St Michael's Hospital, Toronto, Ontario, Canada; 8Center for Clinical Epidemiology and Biostatistics and Abramson Cancer Center, 9University of Pennsylvania; 10Biosample Repository, Fox Chase Cancer Center, Philadelphia, Pennsylvania; 11Faculty of Medicine, University of Southampton, Southampton University Hospitals, NHS Trust, Southampton, United Kingdom; Departments of 12Obstetrics and Gynecology, 13Pathology, and 14Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland; 15Department of Preventive Medicine, Keck School of Medicine, University of Southern California; 16Women's Cancer Program at the Samuel Oschin Cancer Institute and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California; 17Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 18Hormonal and Reproductive Epidemiology Branch, 19Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland; 20Department of Health Sciences Research, 21Laboratory Medicine and Pathology, and 23Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota; 24Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 25Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon/Centre Léon Bérard; 26INSERM U1052, CNRS UMR5286, Université Lyon 1, Cancer Research Center of Lyon; 27Cancer Genetics Network “Groupe Génétique et Cancer”, Fédération Nationale des Centres de Lutte Contre le Cancer, Lyon, France; 28Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne; 29Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 30Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah; 31Department of Epidemiology, Cancer Prevention Institute of California, Fremont, California; 32Dept. of Molecular and Regenerative medicine, Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania; 33Latvian Biomedical Research and Study Centre, Riga, Latvia; 34Genomic Medicine, Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital; 35Department of Clinical Genetics, Rigshospitalet, Copenhagen University, Denmark; 36Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre and Spanish Network on Rare Diseases (CIBERER); 37Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 38Molecular Diagnostics Laboratory, IRRP, National Centre of Scientific Research “Demokritos,” Athens, Greece; 39Unit of Medical Genetics, 40Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT); 41Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO); 42IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan; 43Department of Genetics, Biology and Biochemistry, University of Turin, Turin; 44Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, Aviano (PN); 45Department of Clinical Physiopathology, University of Florence, Florence; 46Department of Molecular Medicine, “Sapienza” University of Rome, Rome, Italy; 47Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ); 48Institute of Human Genetics, Department of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany; 49Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan; 50Family Cancer Clinic, 51Netherlands Cancer Institute, Amsterdam; 52Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam; 53Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; 54Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester; 55Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter; 56Oxford Regional Genetics Service, Churchill Hospital, Oxford; 57All Wales Medical Genetics Services, University Hospital of Wales, Cardiff; 58North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, London; 59Cheshire & Merseyside Clinical Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom; 60Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; 61Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO), University Hospital of Cologne, Cologne; 62Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich, Munich; 63Department of Gynaecology and Obstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden; 64Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel; 65Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf; 66Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm; 67Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover; 68Institute of Human Genetics, University of Münster, Münster; 69Institute of Human Genetics, Campus Virchov Klinikum, Charite Berlin; 70Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University Würzburg, Würzburg, Germany; 71Institute of Cancer Research, Surrey, United Kingdom; 72Service de Génétique Oncologique, 73Unité INSERM U830, Institut Curie; 74Université Paris Descartes, Faculté de Médecine, Paris, France; 75Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; 76Hereditary Cancer Program, Institut Català d'Oncologia, Germans Trias i Pujol Biopmedical research Institute (IGTP), Badalona; 77Hereditary Cancer Program, Institut Català d'Oncologia, Hospital Duran i Reynals - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona; 78Hereditary Cancer Program, Institut Català d'Oncologia, Hospital Josp Trueta - Girona Biomedical Research Institute (IdiBGi), Girona, Spain; 79Department of Pathology, Landspitali, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 80Cancer Genomics Laboratory, 81Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 82Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS; 83Department of Oncology and Surgical Sciences, University of Padua and Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy; 84Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia. 85Center for Medical Genetics, North Shore University Health System, Evanston, Illinois; 86Medical Oncology, Beth Israel Deaconess Medical Center; 87Dana-Farber Cancer Institute, Boston, Massachusetts; 88University of Delaware, Newark, Delaware; 89Epidemiology Research Program, American Cancer Society, Atlanta, Georgia; 90Dept. of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 91Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology and Department of Medical Genetics, St. Petersburg Pediatric Medical Academy, St. Petersburg, Russia; 92Department of Molecular Virology, Immunology and Medical Genetics, 93Department of Internal Medicine, Division of Human Genetics, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio; 94Department of Clinical Genetics, Odense University Hospital, Odense, Denmark; 95Section of Genetic Oncology, Dept. of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy; Departments of 96Clinical Genetics and 97Oncology, Karolinska University Hospital; 98Karolinska University, Stockholm; 99Oncological Centre, Lund University Hospital, Lund, Sweden; 100Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte; 101Department of Medicine, Division of Medical Genetics; 102Departments of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco, California; and Departments of 103Gynecologic Oncology and 104Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
- Corresponding Author:
Antonis C. Antoniou, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom. Phone: 44-0-1223-740-145; Fax: 44-0-1223-740-163; E-mail: antonis{at}srl.cam.ac.uk
January 2012
Volume 21, Issue 1
Volume 21, Issue 1
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Jump to section
Advertisement